London, UK and Boston, MA, USA – November 22, 2022 – Quell Therapeutics Ltd (“Quell”), a leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will participate in two upcoming investor conferences:
- Piper Sandler 34th Annual Healthcare Conference
Format: Company Presentation
Date: Tuesday, November 29, 2022
Time: 1:10 p.m. ET
Location: New York, New York
- 5th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat
Date: Thursday, December 1, 2022
Time: 9:15 a.m. ET
Location: Virtual
About Quell Therapeutics
Quell Therapeutics is a world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.
The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches.
Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com.
ContactsÂ
Luke Henry, Chief Business Officer
Quell Therapeutics
IR@quell-tx.com
Media:Â Mark Swallow, Frazer Hall, Eleanor Perkin
MEDiSTRAVA Consulting
+44 (0) 203 928 6900
Quell-Tx@Medistrava.com
Investors:Â Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200
christina.tartaglia@sternir.com